Screener
4D Molecular Therapeutics FDMT Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $20.54M.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
FAQ
- What is 4D Molecular Therapeutics's total debt?
- 4D Molecular Therapeutics (FDMT) reported total debt of $20.54M in Q1 2026.
- How has 4D Molecular Therapeutics's total debt changed year-over-year?
- 4D Molecular Therapeutics's total debt decreased by 13.9% year-over-year, from $23.85M to $20.54M.
- What is the long-term trend for 4D Molecular Therapeutics's total debt?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total debt has grown at a 3.4% compound annual growth rate (CAGR), from $18.1M to $21.41M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about 4D Molecular Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude